An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum

BACKGROUND: Abemaciclib is a new oral targeted treatment option for patients with advanced breast cancer. The emerging field of oral antitumor therapeutics presents challenges for both patients and healthcare teams; non-adherence and high inter-individual pharmacokinetic variability can influence re...

Descripción completa

Detalles Bibliográficos
Autores principales: Habler, Katharina, Vogeser, Michael, Teupser, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851261/
https://www.ncbi.nlm.nih.gov/pubmed/35199096
http://dx.doi.org/10.1016/j.jmsacl.2022.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851261/
https://www.ncbi.nlm.nih.gov/pubmed/35199096
http://dx.doi.org/10.1016/j.jmsacl.2022.02.001

Ejemplares similares